Castle Biosciences (US.CSTL)
资本配置审计 · 期间： 2017 – 2026
核心指标
US.CSTL · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 404.6% | ↑ |
| ROE | -3.5% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.08 | → |
| Gross Margin | 76.4% | ↓ |
US.CSTL (Castle Biosciences) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 404.6% ↑ ROE -3.5% ↑ Cash Conversion - → D/E Ratio 0.08 → Gross Margin 76.4% ↓
核心指标
US.CSTL (Castle Biosciences) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 404.6% ↑ROE -3.5% ↑Cash Conversion - →D/E Ratio 0.08 →Gross Margin 76.4% ↓免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies